Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.

Saved in:
Bibliographic Details
Main Authors: Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter, Mikko Tuovinen, Anne Pernille Ofstad, Maria Lajer, Christina Shay, Lisette Koeneman, Soulmaz Fazeli Farsani, Leo Niskanen, Sigrun Halvorsen
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Journal of Diabetes Research
Online Access:http://dx.doi.org/10.1155/2024/6142211
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items